|
|
Ceramide stearic to palmitic acid ratio predicts incident diabetes |
|---|---|
| Author: | Hilvo, Mika1; Salonurmi, Tuire2,3,4; Havulinna, Aki S.5; |
| Organizations: |
1Zora Biosciences Oy 2Department of Internal Medicine, Oulu University Hospital 3Research Center for Internal Medicine and Biocenter Oulu
4Medical Research Center Oulu, Oulu University Hospital and University of Oulu
5Department of Public Health Solutions, National Institute for Health and Welfare 6Department of Clinical Science, University of Bergen 7Department of Global Public Health and Primary Care, University of Bergen 8Bevital AS 9Clinical Nutrition and Obesity Center, Kuopio University Hospital 10Institute of Public Health and Clinical Nutrition, University of Eastern Finland 11Joint Municipal Authority for North Karelia Social and Health services 12Department of Heart Disease, Haukeland University Hospital 13Finnish Cardiovascular Research Center, University of Tampere 14Finnish Clinical Biobank Tampere, Tampere University Hospital |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2018080633389 |
| Language: | English |
| Published: |
Springer Nature,
2018
|
| Publish Date: | 2018-08-06 |
| Description: |
AbstractAims/hypothesis: A validated mass-spectrometric method was applied to measure Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0) and Cer(d18:1/24:1) from serum or plasma samples. These ceramides were analysed in a population-based risk factor study (FINRISK 2002, n = 8045), in a cohort of participants undergoing elective coronary angiography for suspected stable angina pectoris (Western Norway Coronary Angiography Cohort [WECAC], n = 3344) and in an intervention trial investigating improved methods of lifestyle modification for individuals at high risk of the metabolic syndrome (Prevent Metabolic Syndrome [PrevMetSyn], n = 371). Diabetes risk score models were developed to estimate the 10 year risk of incident diabetes. Methods: A validated mass-spectrometric method was applied to measure Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0) and Cer(d18:1/24:1) from serum or plasma samples. These ceramides were analysed in a population-based risk factor study (FINRISK 2002, n = 8045), in a cohort of participants undergoing elective coronary angiography for suspected stable angina pectoris (Western Norway Coronary Angiography Cohort [WECAC], n = 3344) and in an intervention trial investigating improved methods of lifestyle modification for individuals at high risk of the metabolic syndrome (Prevent Metabolic Syndrome [PrevMetSyn], n = 371). Diabetes risk score models were developed to estimate the 10 year risk of incident diabetes. Results: Analysis in FINRISK 2002 showed that the Cer(d18:1/18:0)/Cer(d18:1/16:0) ceramide ratio was predictive of incident diabetes (HR per SD 2.23, 95% CI 2.05, 2.42), and remained significant after adjustment for several risk factors, including BMI, fasting glucose and HbA1c (HR 1.34, 95% CI 1.14, 1.57). The finding was validated in the WECAC study (unadjusted HR 1.81, 95% CI 1.53, 2.14; adjusted HR 1.39, 95% CI 1.16, 1.66). In the intervention trial, the ceramide ratio and diabetes risk scores significantly decreased in individuals who had 5% or more weight loss. Conclusions/interpretation: The Cer(d18:1/18:0)/Cer(d18:1/16:0) ratio is an independent predictive biomarker for incident diabetes, and may be modulated by lifestyle intervention. see all
|
| Series: |
Diabetologia |
| ISSN: | 0012-186X |
| ISSN-E: | 1432-0428 |
| ISSN-L: | 0012-186X |
| Volume: | 61 |
| Issue: | 6 |
| Pages: | 1424 - 1434 |
| DOI: | 10.1007/s00125-018-4590-6 |
| OADOI: | https://oadoi.org/10.1007/s00125-018-4590-6 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3121 General medicine, internal medicine and other clinical medicine |
| Subjects: | |
| Funding: |
VS was supported by the Finnish Foundation for Cardiovascular Research. The PrevMetSyn study was supported by grants from the Ministry of Social Affairs and Health (decisions 083/THL/TE/2012 and 201310185), Finland, the Academy of Finland (decision 1114784), the Juho Vainio Foundation, the Sigrid Jusélius Foundation, the Diabetes Research Foundation, the Finnish Foundation for Cardiovascular Research and the City of Oulu, Finland. |
| Academy of Finland Grant Number: |
114784 |
| Detailed Information: |
114784 (Academy of Finland Funding decision) |
| Copyright information: |
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
|
https://creativecommons.org/licenses/by/4.0/ |